Georgia Erbez - 20 Feb 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Director
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Georgia Erbez
Issuer symbol
CHRS
Transactions as of
20 Feb 2024
Net transactions value
$0
Form type
4
Filing time
22 Feb 2024, 17:02:44 UTC
Previous filing
01 Jul 2022
Next filing
05 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +54,000 $0.000000 54,000 20 Feb 2024 Common Stock 54,000 $2.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from February 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.